How Is Ozempic-Related Gastroparesis Diagnosed?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Legal Concerns

If you've been taking Ozempic and are experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether these symptoms point to gastroparesis. This condition, which involves delayed stomach emptying, has been increasingly reported in connection with GLP-1 medications. The legacy of medical and scientific communication has long provided a framework for understanding such drug-related side effects. This page explains how gastroparesis is diagnosed and what the current evidence says about its link to Ozempic.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, under the brand name Wegovy, for chronic weight management. While its efficacy in glycemic control and weight loss is well-documented, a growing body of evidence and clinical reports have raised concerns about a potential link between Ozempic and gastroparesis, a condition characterized by delayed gastric emptying in the absence of a physical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacology of Ozempic, mechanistic pathways that may connect the drug to the condition, and the adequacy of warnings, alongside attorney-related considerations for affected patients in Washington, including the statute of limitations. Gastroparesis is a disorder of the stomach's motility, leading to symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, where a radiolabeled meal is tracked over time, or breath tests measuring carbon dioxide after a labeled meal. The condition can be idiopathic or secondary to diabetes, surgery, or medications. In the context of Ozempic, the drug's mechanism of action—slowing gastric emptying to promote satiety and reduce postprandial glucose excursions—is a double-edged sword. While this effect is therapeutic for weight loss and diabetes, it can, in susceptible individuals, progress to clinically significant gastroparesis.

Pharmacology and Clinical Evidence

The pharmacology of Ozempic involves activation of GLP-1 receptors in the gut, which inhibits gastric motility and secretion. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include delayed gastric emptying. Mechanistic pathways linking Ozempic to gastroparesis are rooted in the drug's effect on the enteric nervous system. GLP-1 receptors are expressed on vagal afferent neurons and enteric neurons, and their activation reduces antral contractions and pyloric tone, leading to slower gastric emptying. In some patients, this pharmacodynamic effect may become pathological, especially if the drug is continued despite symptoms. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for severe gastroparesis-like effects, as retained gastric contents are a hallmark of the condition.

Adequacy of Warnings and Legal Implications

Regarding the adequacy of warnings, the Ozempic label includes a section on gastrointestinal adverse reactions but does not explicitly list gastroparesis as a warning or precaution. The label notes that gastrointestinal adverse reactions are common and often lead to discontinuation, but it does not specifically advise patients or physicians about the risk of developing gastroparesis. The postmarketing data on pulmonary aspiration are included in the warnings and precautions section, but the label states that "available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking RYBELSUS or OZEMPIC tablets, including whether modifying preoperative fasting recommendations or temporarily discontinuing RYBELSUS or OZEMPIC tablets could reduce the incidence of retained gastric contents" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This suggests that the manufacturer acknowledges the potential for delayed gastric emptying but has not provided clear guidance on how to prevent or manage gastroparesis. For patients in Washington who have developed gastroparesis after using Ozempic, attorney-related considerations are critical. The statute of limitations for personal injury claims in Washington is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For product liability claims, including failure to warn, the same three-year limit applies. The timeline between exposure to Ozempic and documented harm is key: patients may have taken the drug for months or years before symptoms of gastroparesis emerged. The injury is often discovered when symptoms become severe enough to require medical evaluation, such as gastric emptying studies. Patients should document the date of first use, the date of symptom onset, and the date of diagnosis. If the diagnosis occurred more than three years ago, the claim may be time-barred. However, Washington law allows for a "discovery rule," which may extend the deadline if the injury was not immediately apparent. In summary, the evidence indicates a plausible link between Ozempic and gastroparesis, supported by the drug's pharmacology and clinical trial data showing high rates of gastrointestinal adverse reactions. The warnings on the label are inadequate in specifically addressing gastroparesis, leaving patients uninformed about this potential risk. Affected individuals in Washington should consult an attorney promptly to assess their claim within the three-year statute of limitations, ensuring that all relevant medical records and timelines are preserved.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Washington?

In Washington, the statute of limitations for personal injury and product liability claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For Ozempic-related gastroparesis, the clock typically starts when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. It is crucial to consult an attorney promptly to preserve your claim.

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a warning or precaution. It mentions gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, and includes postmarketing data on pulmonary aspiration due to retained gastric contents, but does not specifically advise about the risk of developing gastroparesis. This lack of specific warning may be relevant in failure-to-warn claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.